uniQure (NASDAQ:QURE) Director Sells $73,765.56 in Stock

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 2,726 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $73,765.56. Following the completion of the sale, the director owned 32,259 shares of the company’s stock, valued at approximately $872,928.54. This trade represents a 7.79% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Gut also recently made the following trade(s):

• On Wednesday, June 10th, Robert Gut sold 7,552 shares of uniQure stock. The shares were sold at an average price of $26.05, for a total transaction of $196,729.60.

uniQure Stock Up 2.8%

QURE traded up $0.75 on Friday, reaching $27.57. 835,627 shares of the company traded hands, compared to its average volume of 2,601,234. The stock’s 50 day moving average price is $22.31 and its 200-day moving average price is $21.76. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. On average, sell-side analysts expect that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on QURE. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and upped their target price for the company from $12.00 to $35.00 in a research note on Wednesday, March 11th. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $15.00 to $60.00 in a report on Monday, March 9th. Leerink Partners reissued an “outperform” rating and issued a $35.00 price target on shares of uniQure in a report on Monday, March 2nd. Finally, Chardan Capital upped their target price on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $42.83.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp raised its position in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares during the period. CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure in the 3rd quarter valued at approximately $50,000. Torren Management LLC acquired a new stake in shares of uniQure in the 4th quarter valued at approximately $28,000. FNY Investment Advisers LLC raised its position in shares of uniQure by 76.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 718 shares during the period. Finally, IFP Advisors Inc acquired a new stake in shares of uniQure in the 4th quarter valued at approximately $48,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.